🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

38 results for “lenvatinib” Clear

  1. MK-4830, Lenvatinib, Lenvatinib, Belzutifan, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4280A, MK-1308A

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  2. PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , Lenvatinib, BEVACIZUMAB , CAPECITABINE , CARBOPLATIN , FLUOROURACIL , OXALIPLATIN , GEMCITABINE , CISPLATIN , MK-7684A, Lenvatinib

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  3. PACLITAXEL , Lenvatinib, MK-4830, FAMOTIDINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PARACETAMOL , IRINOTECAN , -, Lenvatinib, -, MK-2870

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  4. Postoperative adjuvant lenvatinib

    First Tracks Biotherapeutics

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  5. favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  6. A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Compared to Oral Lenvatinib Capsules in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

    AbbVie Deutschland GmbH & Co. KG

    Squamous-Cell Non-Small Cell Lung Cancer, Hepatocellular Cancer

    phase 1 other active

    1 trial

  7. Bioequivalence of Lenvatinib 10 mg Capsules in Healthy Participants Under Fasting Conditions

    Pharma Mar S.A.

    No medical condition

    phase 1 other active

    1 trial

  8. Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.

    Pharma Mar S.A.

    No medical condition.

    phase 1 other active

    1 trial

  9. Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fasting Conditions.

    Pharma Mar S.A.

    No medical condition.

    phase 1 other active

    1 trial

  10. Bioequivalence of Lenvatinib 10 mg Capsules versus Lenvima® 10 mg Capsules in Healthy Participants Under Fed Conditions

    Pharma Mar S.A.

    No medical condition

    phase 1 other active

    1 trial

  11. Lenvatinib

    First Tracks Biotherapeutics

    Hepatocellular Carcinoma Stage IIIa

    phase 1 small molecule active

    1 trial

  12. CAPECITABINE, CALCIUM FOLINATE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, FLUOROURACIL, Lenvatinib, Lenvatinib, Calciumfolinat-GRY® 100 mg/10 ml Injektionslösung, OXALIPLATIN, Lenvatinib, CALCIUM LEVOFOLINATE , CAPECITABINE

    Merck Sharp and Dohme

    Advanced/Metastatic Gastroesophageal Adenocarcinoma

    approved small molecule active

    1 trial

  13. LENVATINIB, NIVOLUMAB, CABOZANTINIB, LENVATINIB, NIVOLUMAB, AXITINIB, CABOZANTINIB, PEMBROLIZUMAB, IPILIMUMAB, AXITINIB, AXITINIB

    Fondazione Telethon ETS

    metastatic or locally advanced renal cell carcinoma

    approved small molecule active

    1 trial

  14. Tislelizumab combined with Lenvatinib

    China SXT Pharmaceuticals

    Initially Unresectable Hepatocellular Carcinoma

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources